Last reviewed · How we verify
Prevention of CMV Disease in Advanced HIV Patients
Approved treatments
- Cytovene · Roche Palo
GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of CMV Disease in Advanced HIV Patients patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of CMV Disease in Advanced HIV Patients treatment landscape brief
- Prevention of CMV Disease in Advanced HIV Patients treatment updates RSS
Frequently asked questions about Prevention of CMV Disease in Advanced HIV Patients
What drugs treat Prevention of CMV Disease in Advanced HIV Patients?
Tracked treatments include Cytovene.
What is the treatment for Prevention of CMV Disease in Advanced HIV Patients?
Standard treatment for Prevention of CMV Disease in Advanced HIV Patients includes Cytovene. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of CMV Disease in Advanced HIV Patients patent cliff · Prevention of CMV Disease in Advanced HIV Patients CI report
- Treatment: Cytovene · Roche Palo
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing